In the treatment of schizoaffective disorder
Numerical improvement in YMRS score as monotherapy or
adjunctive therapy*†9
YMRS total score: Change from baseline to endpoint (LOCF)†
Among patients with a score ≥16 at baseline.
- Numerical improvement in YMRS total score was larger with INVEGA® compared to placebo, regardless of administration as monotherapy or adjunctive therapy*†
bipolar I disorder.
*The most commonly used mood stabilizers were valproate and lithium. The most commonly used antidepressants were SSRIs and SNRIs. MAOIs were excluded.
†Combined data from two 6-week, randomized, double-blind, placebo-controlled, parallel-group studies. Subjects were nonelderly adults who met DSM-IV criteria for schizoaffective disorder, had a Positive and Negative Syndrome Scale (PANSS) total score of ≥60 and had prominent mood symptoms as confirmed by a score of ≥16 on the Young Mania Rating Scale (YMRS) and/or on the 21-item Hamilton Rating Scale for Depression (HAM-D-21). Subjects received INVEGA® as monotherapy or as an adjunct to mood stabilizers and/or antidepressants. In the flexible-dose study, subjects received flexible INVEGA® doses (3-12 mg daily, n=211) or placebo (n=93). In the 2-dose-level study, subjects received one of two INVEGA® dose levels: 6 mg with option to reduce to 3 mg (n=105), or 12 mg with option to reduce to 9 mg (n=98), or placebo (n=107). Dosing was in the morning without regard to meals. Studies were conducted in the United States, Europe, Russia, and Asia.
